Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Allegra

Showing results (171-180 of 214) with videos related to

Pageof 22
Sort By:
Journal of the National Cancer Institute|November 1, 2014
ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancerLindsay A Renfro, Axel Grothey, Yuan Xue, et al.
Future Oncology (London, England)|November 18, 2022
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trialBrian H Ramnaraign, Ji-Hyun Lee, Azka Ali, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trialJosep Tabernero, Eric Van Cutsem, Radek Lakomý, et al.
JAMA Oncology|December 23, 2016
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical TrialsFrank A Sinicrope, Qian Shi, Carmen J Allegra, et al.
JAMA Oncology|June 9, 2016
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical TrialNan Song, Katherine L Pogue-Geile, Patrick G Gavin, et al.
Journal of Hematology & Oncology|March 9, 2022
BCL-X<sub>L</sub> PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS<sup>G12C</sup>-mutated cancersSajid Khan, Janet Wiegand, Peiyi Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumorsJ L Grem, J M Sorensen, E Cullen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancerCarmen J Allegra, Allyson L Parr, Lester E Wold, et al.
Clinical Therapeutics|August 27, 1999
Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study GroupG Sussman, J Shurman, M R Creed, et al.
Plos One|August 18, 2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutationsRekha Pal, Ning Wei, Nan Song, et al.
Pageof 22

Showing results (171-180 of 214) with videos related to

Sort By:
Pageof 22
Journal of the National Cancer Institute|November 1, 2014
ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancerLindsay A Renfro, Axel Grothey, Yuan Xue, et al.
Future Oncology (London, England)|November 18, 2022
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trialBrian H Ramnaraign, Ji-Hyun Lee, Azka Ali, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2013
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trialJosep Tabernero, Eric Van Cutsem, Radek Lakomý, et al.
JAMA Oncology|December 23, 2016
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical TrialsFrank A Sinicrope, Qian Shi, Carmen J Allegra, et al.
JAMA Oncology|June 9, 2016
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical TrialNan Song, Katherine L Pogue-Geile, Patrick G Gavin, et al.
Journal of Hematology & Oncology|March 9, 2022
BCL-X<sub>L</sub> PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS<sup>G12C</sup>-mutated cancersSajid Khan, Janet Wiegand, Peiyi Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumorsJ L Grem, J M Sorensen, E Cullen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancerCarmen J Allegra, Allyson L Parr, Lester E Wold, et al.
Clinical Therapeutics|August 27, 1999
Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study GroupG Sussman, J Shurman, M R Creed, et al.
Plos One|August 18, 2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutationsRekha Pal, Ning Wei, Nan Song, et al.
Pageof 22